Sales are on a steady path with growth targets both domestically and internationally. The earnings material shows trends in revenue, operating income, ordinary income, net income, by segment trends, cost structure changes, and potential revisions to the outlook for the period.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4985","jir_company_name":"Earth Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4985-20260806-02.pdf","jir_short_summary":"Sales are on a steady path with growth targets both domestically and internationally. The earnings material shows trends in revenue, operating income, ordinary income, net income, by segment trends, cost structure changes, and potential revisions to the outlook for the period.","jir_summary":"### Section heading\nKey highlights show the current status of revenue and various profit indicators, year-over-year trends, regional and product mix movements, changes in cost structure, and potential revisions to the outlook.\n\n### Second section heading\nFuture growth measures include expanding domestic and international markets, strengthening product lines, optimizing promotional expenses, and improving operational efficiency, with emphasis on manufacturing and operations optimization.","jir_financial_highlights":"Revenue: 1,090 hundred million yen (+0.1% (vs. plan))\nGross profit: 472.3 hundred million yen (+)\nSelling, general and administrative expenses: 340.1 hundred million yen (+)\nOperating income: 132.1 hundred million yen (-)\nOrdinary income: 134.8 hundred million yen (-)","jir_category":"","jir_hashtags":"#NoShareBuyback, #Earnings, #BusinessPortfolio, #EarthPharmaceutical","jir_key_figures":"Revenue: 1,090 hundred million yen (vs. plan +0.1%)\nGross profit: 472.3 hundred million yen\nSG&A: 340.1 hundred million yen\nOperating income: 132.1 hundred million yen\nOrdinary income: 134.8 hundred million yen","jir_meta_title":"Earth Pharmaceutical \u2013 Financial Summary for the Second Quarter of the Fiscal Year ending December 2026 | Revenue 1,090 billion yen, Operating income 132.1 billion yen","jir_meta_description":"Earth Pharmaceutical fiscal year 2026 Q2 financial summary. Summary of revenue and profit trends, segment movements, and outlook guidance. Explanations of market environment and cost structure.","jir_og_title":"Earth Pharmaceutical \u2013 Financial Summary | Revenue 1,090 hundred million yen, Operating income 132.1 hundred million yen","jir_og_description":"Earth Pharmaceutical Q2 financial summary. Summary of revenue and various profit indicators and outlook.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"25 Actual\\\",\\\"26 Actual\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[1090,1090],\\\"borderColor\\\":\\\"#1f77b4\\\",\\\"fill\\\":false}]}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"25 Actual\\\",\\\"26 Actual\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating income\\\",\\\"data\\\":[132.1,132.1],\\\"borderColor\\\":\\\"#1f77b4\\\",\\\"fill\\\":false}]}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Profit Margin Analysis\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Gross margin\\\",\\\"Operating margin\\\",\\\"Ordinary margin\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Ratio\\\",\\\"data\\\":[43.3,12.1,?],\\\"backgroundColor\\\":[\\\"#1f77b4\\\",\\\"#2ca02c\\\",\\\"#d62728\\\"]}]}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Segment Revenue Mix\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Domestic\\\",\\\"International\\\",\\\"Other\\\"],\\\"datasets\\\":[{\\\"data\\\":[60,40,?],\\\"backgroundColor\\\":[\\\"#ff6384\\\",\\\"#36a2eb\\\",\\\"#cccccc\\\"]}]}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Projection vs Actual\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"25 Actual\\\",\\\"26 Plan\\\",\\\"26 Actual\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[1090,1090,1090],\\\"borderColor\\\":\\\"#1f77b4\\\",\\\"fill\\\":false}]}}\"}]","ir_related_company":9486,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-97505","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n